Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1184-1195
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1184
Table 1 Basic characteristics according to anatomical location using the modified Lauren classification
Variable
Distal non-diffuse type
Proximal non-diffuse type
Diffuse type
Gender (%)
Male416 (63.6)324 (70.0)848 (53.0)
Female238 (36.4)139 (30.0)753 (47.0)
Age (%)
< 60 yr200 (30.6)167 (36.1)850 (53.1)
≥ 60 yr454 (69.4)296 (63.9)751 (46.9)
Tumor size (%)
< 4.0 cm318 (48.6)218 (47.1)664 (41.5)
≥ 4.0 cm310 (47.4)221 (47.7)771 (48.2)
Unknown26 (4.0)24 (5.2)166 (10.4)
Retrieved lymph nodes (%)
Adequate (n ≥ 16) 326 (49.8)261 (56.4)831 (51.9)
Inadequate (n < 16)328 (50.2)202 (43.6)770 (48.1)
AJCC 8th pT stage (%)
pT1211 (32.3)123 (26.6)356 (22.2)
pT287 (13.3)69 (14.9)173 (10.8)
pT3207 (31.7)149 (32.2)464 (29.0)
pT4a101 (15.4)89 (19.2)480 (30.0)
pT4b48 (7.3)33 (7.1)128 (8.0)
AJCC 8th pN stage (%)
pN0302 (46.2)197 (42.5)532 (33.2)
pN1117 (17.9)79 (17.1)260 (16.2)
pN2115 (17.6)90 (19.4)302 (18.9)
pN3a95 (14.5)70 (15.1)347 (21.7)
pN3b25 (3.8)27 (5.8)160 (10.0)
Differentiation grade (%)
Well differentiation66 (10.1)26 (5.6)3 (0.2)
Moderate differentiation269 (41.1)170 (36.7)44 (2.7)
Poor differentiation311 (47.6)259 (55.9)1484 (92.7)
Undifferentiation8 (1.2)8 (1.7)70 (4.4)
Table 2 Univariate and multivariable analyses of prognostic factors for overall survival
VariableNo. of patients (%)Univariate analysis
Multivariate analysis
5-yr OS
P value
HR (95%CI)
P value
Gender (%)0.111
Male1588 (58.4)45.9%
Female1130 (41.6)49.1%
Age (%)< 0.001< 0.001
< 60 yr1217 (44.8)50.7%1 (Ref)
≥ 60 yr1501 (55.2)44.4%1.157 (1.360–1.692)< 0.001
Tumor size (%)< 0.0010.001
≤ 4.0 cm1200 (44.2)63.9%1 (Ref)
> 4.0 cm1302 (47.9)33.6%1.179 (1.038–1.339)0.011
Unknown216 (7.9)40.2%1.457 (1.191–1.782)< 0.001
Retrieved lymph nodes (%)0.074< 0.001
Adequate (n ≥ 16)1418 (52.2)48.9%1 (Ref)
Inadequate (n < 16)1300 (47.8)45.5%1.550 (1.380–1.740)< 0.001
AJCC 8th pT stage (%)< 0.001< 0.001
pT1690 (25.4)80.9%1 (Ref)
pT2329 (12.1)66.6%1.535 (1.193–1.975)0.001
pT3820 (30.2)38.5%2.882 (2.334–3.558)< 0.001
pT4a670 (24.7)23.4%3.415 (2.740–4.256)< 0.001
pT4b209 (7.7)18.6%4.452 (3.458–5.732)< 0.001
AJCC 8th pN stage (%)< 0.001< 0.001
pN01031 (37.9)71.6%1 (Ref)
pN1456 (16.8)46.9%1.467 (1.225–1.757)< 0.001
pN2507 (18.7)37.5%1.611 (1.353–1.919)< 0.001
pN3a512 (18.8)24.8%2.356 (1.976–2.809)< 0.001
pN3b212 (7.8)9.2%4.138 (3.306–5.181)< 0.001
Differentiation grade (%)0.0110.135
Well differentiation95 (3.5)69.4%1 (Ref)
Moderate differentiation483 (17.8)58.9%0.974 (0.649–1.462)0.898
Poor differentiation2054 (75.5)44.0%1.123 (0.755–1.670)0.566
Undifferentiation86 (3.2)35.6%1.415 (0.876–2.285)0.156
Modified Lauren classification (%)< 0.0010.013
Distal non-diffuse type654 (24.1)58.8%1 (Ref)
Proximal non-diffuse type463 (17.0)48.3%1.230 (1.033–1.466)0.020
Diffuse type1601 (58.9)42.4%1.246 (1.068–1.452)0.005
Table 3 Comparison of predictive performances between different pathological classifications and prognostic models
Pathological classification/prognostic modelAUC (95%CI)
AIC
3-yr overall survival
5-yr overall survival
Differentiation grade0.626 (0.608–0.644)0.621 (0.602–0.639)25971
Lauren classification0.666 (0.647–0.683)0.681 (0.663–0.699)25923
Modified Lauren classification0.679 (0.661–0.696)0.702 (0.685–0.719)25877
DeLong tests for AUCs
Differentiation grade vs LaurenP < 0.001P < 0.001
Lauren vs modified LaurenP < 0.001P < 0.001
Modified Lauren vs differentiation gradeP < 0.001P < 0.001
Novel prognostic model 0.803 (0.786–0.819)0.804 (0.787–0.820)20010
Age, tumor size, retrieved lymph nodes, pT stage, pN stage, modified Lauren classification
Control model0.776 (0.759–0.793)0.776 (0.759–0.793)20144
AJCC 8th pTNM stage (pT stage, pN stage)